Effects of nabumetone on platelet function in healthy volunteers.

Non-steroidal anti-inflammatory drugs (NSAID) are frequently prescribed but gastrointestinal haemorrhages and inhibition of platelet function are two side effects that limit their use. Nabumetone belongs to a new prostaglandin-sparing class of NSAID with a low potential for causing gastrointestinal mucosal irritancy and inhibition of platelet function. We have used flow cytometry and in vitro bleeding time (IVBT) to measure the effects of nabumetone on platelet function in healthy volunteers. Nabumetone was found to cause a significant decrease in platelet-bound fibrinogen after adenosine diphosphate (ADP) activation using flow cytometry and a significant increase in IVBT when using CaCl(2) as activating substance. The platelet inhibitory effect was less pronounced than the changes seen with low dose aspirin. Flow cytometry and IVBT are two sensitive methods well suited for clinical use and could both be used to monitor drug-induced inhibition of platelet function.

[1]  C. Patrono,et al.  Effects of nabumetone on prostanoid biosynthesis in humans , 1995, Clinical pharmacology and therapeutics.

[2]  H. Weisman,et al.  New Antiplatelet Agents: Platelet GPIIb/llla Antagonists , 1995, Thrombosis and Haemostasis.

[3]  S. Roth.  From Peptic Ulcer Disease to NSAID Gastropathy , 1995 .

[4]  E. Mammen,et al.  Clinical Experience with the Thrombostat 4000 , 1995, Seminars in Thrombosis & Hemostasis.

[5]  V. Kretschmer,et al.  Hemostaseological Management of Urological Operations in Patients Taking Aspirin Using the Thrombostat 4000 , 1995, Seminars in Thrombosis & Hemostasis.

[6]  V. Kretschmer,et al.  Desmopressin Effect on Acetylsalicylic Acid Impaired Platelet Punction , 1995, Seminars in Thrombosis & Hemostasis.

[7]  D. Jorkasky,et al.  Comparative Effects of Nabumetone, Sulindac, and Indomethacin on Urinary Prostaglandin Excretion and Platelet Function in Volunteers , 1994, Journal of clinical pharmacology.

[8]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[9]  R. Melarange,et al.  Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration. , 1994, European journal of rheumatology and inflammation.

[10]  T. Lindahl,et al.  Inhibition of fibrinogen binding to platelets by MK-852, a new GPIIb/IIIa antagonist. , 1994, Upsala journal of medical sciences.

[11]  E. Topol,et al.  Clinical Trials of Platelet Receptor Inhibitors , 1993, Thrombosis and Haemostasis.

[12]  S. Dahl.  Nabumetone: A “Nonacidic” Nonsteroidal Antiinflammatory Drug , 1993, The Annals of pharmacotherapy.

[13]  L. Wallentin,et al.  Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia , 1992, The Lancet.

[14]  T. Lindahl,et al.  Studies of Fibrinogen Binding to Platelets by Flow Cytometry: An Improved Method for Studies of Platelet Activation , 1992, Thrombosis and Haemostasis.

[15]  S. E. Lind,et al.  The bleeding time does not predict surgical bleeding (see comments) , 1991 .

[16]  M. Webley,et al.  A comparative study of nabumetone and indomethacin in ankylosing spondylitis. , 1991, European journal of rheumatology and inflammation.

[17]  C. Abrams,et al.  Direct detection of activated platelets and platelet-derived microparticles in humans. , 1990, Blood.

[18]  V. Kretschmer,et al.  In vitro bleeding test--a simple method for the detection of aspirin effects on platelet function. , 1989, Thrombosis research.

[19]  M. Kratzer,et al.  Simulation of primary haemostasis in vitro. , 1985, Haemostasis.